3D printing technology in healthcare: applications, regulatory understanding, IP repository and clinical trial status

被引:36
作者
Kumar Gupta, Dipak [1 ]
Ali, Mohd Humair [1 ]
Ali, Asad [1 ]
Jain, Pooja [1 ]
Anwer, Md. Khalid [2 ]
Iqbal, Zeenat [1 ]
Mirza, Mohd. Aamir [1 ]
机构
[1] Jamia Hamdard, Sch Pharmaceut Educ & Res SPER, Dept Pharmaceut, New Delhi, India
[2] Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Dept Pharmaceut, Alkharj, Saudi Arabia
关键词
Additive manufacturing; biomaterials; drug products; medical devices; surgery; polymers; tissue engineering; DRUG-RELEASE CHARACTERISTICS; INNOVATIVE APPROACH; LOADED HYDROGELS; LOCAL-DELIVERY; DOSAGE FORMS; TABLETS; SURGERY; INKJET; FABRICATION; DEVICES;
D O I
10.1080/1061186X.2021.1935973
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Mass consumerization of three-dimensional (3D) printing innovation has revolutionised admittance of 3D-printing in an expansive scope of ventures. When utilised predominantly for industrial manufacturing, 3D-printing strategies have rapidly attained acquaintance in different parts of health care industry. 3D-printing is a moderately new technology that has discovered promising applications in the medication conveyance and clinical areas. This review intends to explore different parts of 3D- printing innovation concerning pharmaceutical and clinical applications. Review on pharmaceutical products like tablets, caplets, films, polypills, microdots, biodegradable patches, medical devices (uterine and subcutaneous), patient specific implants, cardiovascular stents, etc. and prosthetics/anatomical structures, surgical models, organs and tissues created utilising 3D-printing is being presented. In addition, the regulatory understanding and current IP and clinical trial status pertaining to 3D fabricated products/medical applications have also been funnelled, garnering information from different web portals of regulatory agencies and databases. It is additionally certain that for such new innovations, there would be difficulties and questions before these are acknowledged as protected and viable. The circumstance demands purposeful and wary endeavours to acquire regulations which would at last prompt the accomplishment of this progressive innovation, thus various regulatory challenges faced have been conscientiously discussed.
引用
收藏
页码:131 / 150
页数:20
相关论文
共 118 条
  • [31] Anti-tuberculosis drug combination for controlled oral delivery using 3D printed compartmental dosage forms: From drug product design to in vivo testing
    Genina, Natalja
    Boetker, Johan Peter
    Colombo, Stefano
    Harmankaya, Necati
    Rantanen, Jukka
    Bohr, Adam
    [J]. JOURNAL OF CONTROLLED RELEASE, 2017, 268 : 40 - 48
  • [32] Behavior of printable formulations of loperamide and caffeine on different substrates-Effect of print density in inkjet printing
    Genina, Natalja
    Fors, Daniela
    Palo, Mirja
    Peltonen, Jouko
    Sandler, Niklas
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 453 (02) : 488 - 497
  • [33] Applications of 3D printing in cardiovascular diseases
    Giannopoulos, Andreas A.
    Mitsouras, Dimitris
    Yoo, Shi-Joon
    Liu, Peter P.
    Chatzizisis, YiannisS.
    Rybicki, Frank J.
    [J]. NATURE REVIEWS CARDIOLOGY, 2016, 13 (12) : 701 - 718
  • [34] 3D printed oral solid dosage forms containing hydrochlorothiazide for controlled drug delivery
    Gioumouxouzis, Christos I.
    Katsamenis, Orestis L.
    Bouropoulos, Nikolaos
    Fatouros, Dimitrios G.
    [J]. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2017, 40 : 164 - 171
  • [35] Patient acceptability of 3D printed medicines
    Goyanes, Alvaro
    Scarpa, Mariagiovanna
    Kamlow, Michael
    Gaisford, Simon
    Basit, Abdul W.
    Orlu, Mine
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 530 (1-2) : 71 - 78
  • [36] Development of modified release 3D printed tablets (printlets) with pharmaceutical excipients using additive manufacturing
    Goyanes, Alvaro
    Fina, Fabrizio
    Martorana, Annalisa
    Sedough, Daniel
    Gaisford, Simon
    Basit, Abdul W.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2017, 527 (1-2) : 21 - 30
  • [37] Fused-filament 3D printing of drug products: Microstructure analysis and drug release characteristics of PVA-based caplets
    Goyanes, Alvaro
    Kobayashi, Masanori
    Martinez-Pacheco, Ramon
    Gaisford, Simon
    Basit, Abdul W.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 514 (01) : 290 - 295
  • [38] 3D scanning and 3D printing as innovative technologies for fabricating personalized topical drug delivery systems
    Goyanes, Alvaro
    Det-Amornrat, Usanee
    Wang, Jie
    Basit, Abdul W.
    Gaisford, Simon
    [J]. JOURNAL OF CONTROLLED RELEASE, 2016, 234 : 41 - 48
  • [39] Fabrication of controlled-release budesonide tablets via desktop (FDM) 3D printing
    Goyanes, Alvaro
    Chang, Hanah
    Sedough, Daniel
    Hatton, Grace B.
    Wang, Jie
    Buanz, Asma
    Gaisford, Simon
    Basit, Abdul W.
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 496 (02) : 414 - 420
  • [40] 3D printing of modified-release aminosalicylate (4-ASA and 5-ASA) tablets
    Goyanes, Alvaro
    Buanz, Asma B. M.
    Hatton, Grace B.
    Gaisford, Simon
    Basit, Abdul W.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2015, 89 : 157 - 162